Zanzalintinib (XL092)

Name: Zanzalintinib (XL092) in Metastatic colorectal cancer: BRAF-directed combination therapy
Published: 2026-09-14T15:39:06-04:00

Metastatic colorectal cancer

Manufacturer: Exelixis
Regulatory submission: NDA submitted December 2025
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Approaches to treatment Current treatment options and standard of care

BRAF-directed combination therapy

1 evidence topic · 1 source

Encorafenib traditional approval: combination and biomarker requirements

“in combination with cetuximab and fluorouracil-based chemotherapy” (opens the source at this quote in a new tab)
“with a BRAF V600E mutation, as detected by an FDA-authorized test.” (opens the source at this quote in a new tab)